Janssen Presents Efficacy and Subgroup Analyses from MAIA St

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab)...

Related Keywords

Virginia , United States , American , Goldschmidth Daratumumab , Shaji Kumar , Mark Wildgust , Christie Corbett , Global Medical Affairs , Janssen Biotech Inc , American Society Of Hematology Annual Meeting , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , American Society Of Hematology , Division Of Hematology , National Comprehensive Cancer Network , American Cancer Society , None Of The Janssen Pharmaceutical Companies , Department Of Internal Medicine , Drug Administration , International Staging System , Exchange Commission , Companies Of Johnson , Johnson , Weiselk Health , American Society , Internal Medicine , Vice President , Janssen Research , New England Journal , Lancet Oncology , Janssen Biotech , National Comprehensive Cancer , Interference With Serological , With Determination , Pharmaceutical Companies , Infectious Diseases , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Plus Lenalidomide , Versus Lenalidomide , Transplant Ineligible Patients , Newly Diagnosed Multiple Myeloma , Updated Analysis , Hematology Annual , With Newly Diagnosed Multiple Myeloma , Clinical Assessment , Key Subgroups , Related Quality , Frail Transplant Ineligible Patients , Subgroup Analysis , Prescribing Information , Accessed December , Statistics About Multiple Myeloma , The Janssen Pharmaceutical Companies Of Johnson Amp ,